The Kolkata Patent Office has refused divisional patents related to Swiss pharmaceutical company Roche’s breast cancer drug Herceptin.
Eversheds has appointed the former head of Sidley Austin's London IP and life sciences team Brett Rowland, as a partner.
On August 5, Swiss pharmaceutical company Roche signed an agreement with the MPP to increase access to its drug valganciclovir (Valcyte), an oral medicine for the treatment of preventable viral infection cytomegalovirus (CMV).
India’s Intellectual Property Appeal Board has revoked a patent covering GlaxoSmithKline’s breast cancer drug Tykerb, in the latest blow to western pharmaceutical companies in India.
The Intellectual Property Appellate Board in Chennai has cancelled two trademarks associated with versions of Viagra.
The Court of Appeal for England and Wales has upheld the Patent Court’s decision that Teva Pharmaceutical Industries’ UK patent 762,888, relating to the multiple sclerosis drug Copaxone, is valid.
A US court has ruled that an Israeli company’s patent for a multiple sclerosis (MS) drug is invalid, paving the way for rivals to market a generic version.
A US court has upheld a decision ruling that a continuation patent filed by a bio-tech company is invalid.
The chair of the FTC has said it will continue to challenge pay-for-delay court settlements in the pharmaceutical industry and has hailed a Supreme Court ruling as a victory for consumers.
A white paper suggests that patent case settlements between originator pharmaceutical companies and their generic competitors may be beneficial to drug consumers.